What Is Ernexa Therapeutics Inc. (ERNA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Ernexa Therapeutics Inc.'s intrinsic value is estimated at $4.88. Trading at its current price of $6.73, the valuation engine raises significant caution: 7 of 9 models flag downside risk, projecting an average implied return of -27.5%. The most optimistic model, CUCE, places fair value at $17.63 (+162.0%), while ML-RIV — the most conservative — estimates $0.01 (-99.8%). This +261.8% gap reflects genuine analytical uncertainty about Ernexa Therapeutics Inc.'s intrinsic worth.
What Do the Models Say About ERNA?
9 of 13 models are currently active for ERNA. Of these, 2 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates ERNA's intrinsic value at $2.23, implying -66.9% downside from the current price. See which stocks rank higher →
How Does ERNA Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, ERNA ranks #219 by Quality of Company score. CirclFi's QOC score of 4.9/10 evaluates 32 fundamental signals. A score of 4.9 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Ernexa Therapeutics Inc.'s positioning within the Pharmaceutical Preparations segment means that pipeline depth and stage distribution plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.
Is ERNA a Value Trap?
CirclFi's Value Trap algorithm assigns ERNA a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Ernexa Therapeutics Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Ernexa Therapeutics Inc. earns a quality score of 4.9/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +261.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ERNA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ERNA's 9 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad